Correction: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors - Summary - MDSpire

Correction: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors

  • By

  • Darren Hargrave

  • Lynley V. Marshall

  • Nicolas André

  • Julie Krystal

  • Brian H. Ladle

  • Karen A. Robbins

  • Stephan Hois

  • Jon Armstrong

  • Sarah Donegan

  • June 9, 2026

  • 0 min

Share

Objective:

Erratum for the Phase I/II multicenter study evaluating durvalumab and tremelimumab in pediatric patients with advanced solid tumors.

Key Findings:
  • Table 1 had misaligned numerical values and a missing footnote related to histology.
Interpretation:

Limitations:
Conclusion:

The erratum corrects specific inaccuracies in the published data.

Original Source(s)

Correction: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors

  • by Darren Hargrave, Lynley V. Marshall, Nicolas André, Julie Krystal, Brian H. Ladle, Karen A. Robbins, Stephan Hois, Jon Armstrong, Sarah Donegan

  • June 9, 2026

Related Content

“Assessment of an EMR-integrated Onco-Insight hospital-based cancer registry system for data completeness and data entry turnaround time at a tertiary care cancer center in India”

This Week’s Biopharma News: Big Moves in Bispecifics

Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody

  • June 9, 2026

  • 5 min
Baseline vs. on-treatment heart failure with preserved ejection fraction (HFpEF) in a real world cardio-oncology clinic: observational analysis of cancer therapy-related cardiovascular toxicity incidence and cancer treatment implications